Mental Disorders: Managing Chronic Disease Program

Warning message

Please Log in to purchase access to this course.
$175.00

This program has as focus on the pharmacist's role in the are of people with insomnia, anxiety, and depression.   This will include a review of the clinical features of depression and anxiety, their pharmacotherapies and tools are resources that pharmacists can recommend for self-help.  The management of insomnia, pharmacotherapy and their discontinuation.  

Learning Objectives:

Deepen their understanding of their patient’s personal experiences and health needs associated with living with insomnia, anxiety, and depression

Expand their awareness of and ability to recommend non-pharmacological options for people with insomnia, anxiety, and depression

Be able to support and guide patients initiating, maintaining, and discontinuing antidepressants and sedative-hypnotics

Learn about and how to use psychotropic treatment tools that support patient engagement, assessment, communications, and follow-up

Apply knowledge in the management of selected treatment issues including partial treatment response, polypharmacy, withdrawal, and management of adverse effects of antidepressants and sedative-hypnotics. 

 

Author:  Dr. David Gardner,  Professor of Psychiatry and Pharmacy, Dalhousie University

Dr. David Gardner is a Professor with the Department of Psychiatry and has a joint appointment with the College of Pharmacy at Dalhousie University. He is an active researcher and educator with over 80 peer-reviewed publications and multiple active research projects. His program of research focuses on the safe, effective, and rational use of psychotropic medications as well as capacity building in community mental health and addictions care and services. He is the co-lead and co-developer of the Bloom Program, the mental health and addictions community pharmacy partnership program of Nova Scotia, which represents a first-of-its-kind model of care that optimizes the role of the community pharmacist. He has been investigating the community pharmacist’s role and experiences in the care of people at risk of suicide and he leads Sleepwell, a program that aims to decrease sleep medication use across Canada while increasing the utilization of evidence-based self-help cognitive-behavioural therapy for insomnia tools. Dr. Gardner is an executive member of the Canadian Deprescribing Network and author of the book Antipsychotics and Their Side Effects. He has received several awards, locally and nationally, for his teaching excellence. At Dalhousie, he is responsible for clinical psychopharmacology teaching to psychiatry residents and medical and pharmacy students, and he also teaches courses in critical appraisal of the medical literature. In 2012, Dr. Gardner was recognized by the Canadian Pharmacists Association as Pharmacist of the Year for his leadership and achievements in mental health and he was a founding member of the Science Advisory Committee of the Mental Health Commission of Canada. 

This program has been accredited by Dalhousie Continuing Pharmacy Education for 3.0 CEUs.